Table 1.

Patient demographics and baseline characteristics.

Eribulin + pembrolizumab
Phase IbPhase IITotal
Parameter(n = 7)(n = 160)(N = 167)
Age, years
 Median (range)54 (44–65)56 (32–88)56 (32–88)
Sex, female, n (%)7 (100)160 (100)167 (100)
Race, n (%)
 White7 (100)134 (83.8)141 (84.4)
 Black or African American019 (11.9)19 (11.4)
 Asian01 (0.6)1 (0.6)
 Other06 (3.8)6 (3.6)
ECOG PS, n (%)
 04 (57.1)102 (63.8)106 (63.5)
 13 (42.9)57 (35.6)60 (35.9)
 201 (0.6)1 (0.6)
PD-L1–expression statusa, n (%)
 Positive3 (42.9)71 (44.4)74 (44.3)
 Negative2 (28.6)73 (45.6)75 (44.9)
 Not available2 (28.6)16 (10.0)18 (10.8)
Phase II enrollment strata, n (%)
 Stratum 1b3 (42.9)63 (39.4)66 (39.5)
 Stratum 2c4 (57.1)97 (60.6)101 (60.5)
  • Abbreviations: CPS, combined positive score; ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, programmed death-ligand 1.

  • aTumor samples with evaluable PD-L1 status were available from 149 patients, of which 63% were primary tumor samples and 37% were metastatic. PD-L1 status was considered positive if the CPS was ≥1 and negative if CPS was <1.

  • bNo prior systemic anticancer therapy for metastatic disease.

  • c1–2 prior systemic anticancer therapies for metastatic disease.